Back to Gastroenterology

OUR EXPERTISE AND AND SERVICES AVAILABLE IN

Inflammatory Bowel Disease

Overview

Spherix’s coverage of the inflammatory bowel disease market monitors the evolving landscape of ulcerative colitis and Crohn’s disease management with advanced therapies.  We specifically track how new therapies influence changes in gastroenterologists’ attitudes and ultimately treatment decision-making.

Services Available

Trending market evolution

  • Crohn's Disease (US) - quarterly, n=100

  • Crohn's Disease (EU) - semiannual, n=250

  • Ulcerative Colitis (US) - quarterly, n=100

  • Ulcerative Colitis (EU) - semiannual, n=250

Exploring the patient journey

  • Biologic/Small Molecule New Starts in IBD (US) - annual, n=1,000 patient charts

  • Biologic/Small Molecule Switching in IBD (US) - annual, n=1,000 patient charts

  • Biologic/Small Molecule Switching in IBD (EU) - annual, n=1,250 patient charts

Benchmarking new brand performance

  • Stelara (Janssen) in Ulcerative Colitis (US)

  • Zeposia (BMS) in Ulcerative Colitis (US)*

*Pending approvals and launch

Learn more about our services

  • HOW CAN WE PARTNER TOGETHER?

    Get more information on Inflammatory Bowel Disease Coverage